Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF.

Lung Cancer. 2018 Aug;122:67-71. doi: 10.1016/j.lungcan.2018.05.020. Epub 2018 May 22.


Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.


PD-1/PD-L1 Axis in Lung Cancer.

Santini FC, Hellmann MD.

Cancer J. 2018 Jan/Feb;24(1):15-19. doi: 10.1097/PPO.0000000000000300. Review.


Endocrine side effects of cancer immunotherapy.

Cukier P, Santini FC, Scaranti M, Hoff AO.

Endocr Relat Cancer. 2017 Dec;24(12):T331-T347. doi: 10.1530/ERC-17-0358. Epub 2017 Oct 12. Review.


Atezolizumab for the treatment of non-small cell lung cancer.

Santini FC, Rudin CM.

Expert Rev Clin Pharmacol. 2017 Sep;10(9):935-945. doi: 10.1080/17512433.2017.1356717. Epub 2017 Jul 27. Review.


Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Santini FC, Kunte S, Drilon A.

Transl Lung Cancer Res. 2017 Jun;6(3):393-395. doi: 10.21037/tlcr.2017.04.06. No abstract available. Erratum in: Transl Lung Cancer Res. 2017 Oct;6(5):611.


The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.

Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A.

Onco Targets Ther. 2017 Apr 6;10:1983-1992. doi: 10.2147/OTT.S109295. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center